Ecdysterone and LGD-4033 Interaction

Avoid
Mechanism-based 64% confidence

Ecdysterone and LGD-4033 have a potentially harmful interaction with 64% confidence. Both Ecdysterone and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

Ecdysterone

Phytoecdysteroid | Natural Anabolic & Performance Enhancer

Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling.

Half-life: ~4-9 hours Typical dose: 500-1000 mg/day (oral) or 50-100 mg/day (injectable) anabolic
estrogen receptormtorngf androgenichepatotoxichpta suppressivelipid disrupting
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate

Shared Safety Flags

2x 2 androgenic compounds (Ecdysterone, LGD-4033). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 hepatotoxic compounds (Ecdysterone, LGD-4033). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (Ecdysterone, LGD-4033). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Ecdysterone, LGD-4033). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Ecdysterone, LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take Ecdysterone with LGD-4033?

Combining Ecdysterone with LGD-4033 is not recommended. Both Ecdysterone and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Ecdysterone and LGD-4033 safe together?

This combination carries significant risk. Both Ecdysterone and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Ecdysterone and LGD-4033?

Both Ecdysterone and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Ecdysterone and LGD-4033?

Ecdysterone has a half-life of ~4-9 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Ecdysterone vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.